Literature DB >> 19584061

Referrals into a dedicated British penile cancer centre and sources of possible delay.

M A Lucky1, B Rogers, N J Parr.   

Abstract

OBJECTIVE: To assess sources of delay in referral to a specialist Urology clinic for penile cancer.
METHODS: Patients with penile cancer seen during the period December 2002 to December 2007 were identified from the unit's database. Information regarding presentation, diagnosis and pattern of referral was retrieved from records. Delay was defined as the time between the patient first noticing a penile lesion and date of first seeking medical advice, or additional time before being seen by a Urologist resulting from referral to another specialty.
RESULTS: Of 100 patients, with a median age of 54 years (range 2-81 years), 19% were initially referred to other specialties (Genitourinary Medicine-13%, Dermatology-4%, Plastics 2%). Initial referrals to Genito-urinary Medicine and Dermatology resulted in mean delays of 6 and 3.5 months respectively, whereas the mean duration for patients to present to any medical practitioner from onset of symptoms was 5.8 months. Overall, 47% presented with locally advanced disease.
CONCLUSION: Approximately one-fifth of patients with penile cancer are first referred to specialties other than Urology. This sometimes delays diagnosis, potentially affecting overall prognosis. The major source of delay, however, results from patient reluctance to seek medical advice. Thus, the greatest impact in this condition is likely to be achieved by increased public awareness and education.

Entities:  

Mesh:

Year:  2009        PMID: 19584061     DOI: 10.1136/sti.2009.036061

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  9 in total

Review 1.  [Penile dermatoses].

Authors:  K Kühborth; G Haidl; J-P Allam
Journal:  Urologe A       Date:  2015-05       Impact factor: 0.639

2.  Radiotherapy plus chemotherapy versus chemotherapy alone in penile cancer patients with extracapsular nodal extension after inguinal lymph node surgery: a multi-institutional study.

Authors:  Zai-Shang Li; Xue-Ying Li; Bin Wang; Peng Chen; Xiang Li; Ornellas Antonio Augusto; Zi-Ke Qin; Zhuo-Wei Liu; Yong-Hong Li; Hui Han; Fang-Jian Zhou
Journal:  World J Urol       Date:  2020-04-17       Impact factor: 4.226

Review 3.  Penile cancer: current therapy and future directions.

Authors:  G Sonpavde; L C Pagliaro; C Buonerba; T B Dorff; R J Lee; G Di Lorenzo
Journal:  Ann Oncol       Date:  2013-01-04       Impact factor: 32.976

4.  [Lymph-node-positive penile cancer : Management and systemic therapy].

Authors:  A Aziz; S Milerski; K Kernig; C Protzel; O W Hakenberg
Journal:  Urologe A       Date:  2018-04       Impact factor: 0.639

5.  Underutilization of Surgical Standard of Care for Insured Men with Invasive Penile Cancer.

Authors:  Edward K Chang; Rishi R Sekar; Sarah K Holt; John L Gore; Jonathan L Wright; Yaw A Nyame
Journal:  Urol Pract       Date:  2021-05-01

6.  Proposal for reclassification of N staging system in penile cancer patients, based on number of positive lymph nodes.

Authors:  Zhiyong Li; Shengjie Guo; Zhiming Wu; Hui Han; Zaishang Li; Yanjun Wang; Jieping Chen; Chuangzhong Deng; Zike Qin; Zhuowei Liu; Yonghong Li; Dong Chen; Fangjian Zhou; Kai Yao
Journal:  Cancer Sci       Date:  2018-02-05       Impact factor: 6.716

Review 7.  The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.

Authors:  Sudeh Izadmehr; Dara J Lundon; Nihal Mohamed; Andrew Katims; Vaibhav Patel; Benjamin Eilender; Reza Mehrazin; Ketan K Badani; John P Sfakianos; Che-Kai Tsao; Peter Wiklund; William K Oh; Carlos Cordon-Cardo; Ashutosh K Tewari; Matthew D Galsky; Natasha Kyprianou
Journal:  Front Oncol       Date:  2021-09-27       Impact factor: 6.244

Review 8.  Triaging urological surgeries to cope with the coronavirus-19 pandemic.

Authors:  Jesse Spooner; Tarek Lawen; Jesse Ory
Journal:  Curr Opin Urol       Date:  2022-03-01       Impact factor: 2.309

9.  Management of urologic cancers during the pandemic and potential impact of treatment deferrals on outcomes.

Authors:  Badar M Mian; Sana Siddiqui; Ardalan E Ahmad
Journal:  Urol Oncol       Date:  2020-10-28       Impact factor: 3.498

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.